Telemonitoring and education to guide treatment for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to under 75 years old
- You have ulcerative colitis that’s been active and not well controlled for at least 3 months
- You plan to start adalimumab (Humira) for the first time, and you’ve never used anti-TNF medicines or other UC biologics that work for UC (except vedolizumab)
- You haven’t used JAK inhibitor medicines (for example, tofacitinib or similar) before
- You’ve tried steroids and/or certain UC medicines (like azathioprine or 6-mercaptopurine, methotrexate, or vedolizumab) but they didn’t work or you couldn’t tolerate them—or you didn’t respond to an adequate steroid course
- You can use a smartphone and the internet, and you agree to write consent; if you can get pregnant, you’ll use contraception during the whole study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests new medicines for people with moderate to severe ulcerative colitis who haven't found relief with standard treatments. Participants will receive one of several investigational drugs (these are not yet approved and are being studied for safety and tolerability). The goal is to see if the drugs are safe and if they might help control symptoms.
This trial tests whether remote monitoring, using an app and home stool tests, can be a safe alternative to frequent clinic visits for people with stable IBD. If you qualify, you'll have fewer in-person appointments and more flexibility.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.